In primary hippocampal neurons, over-expression of the dominant-negative Rac1 mutant or the presence of Rac1 inhibitors decreased the levels of APP mRNA, indicting Rac1 could be a potential drug target for AD therapy[100]. Here, RAC1 is linked to Alzheimer disease.